News

News and Press Releases
Research | Antibiotics | Our Research Approach CF Foundation Awards Up to $5.6 Million to Develop Novel Antibiotic to Fight Drug-Resistant Bacteria

The Cystic Fibrosis Foundation has awarded up to $5.6 million to Microbion Corporation to develop a novel, inhaled antibiotic to treat drug-resistant bacterial infections in people with cystic fibrosis.

| 2 min read
About the CF Foundation | Drug Pipeline | Antibiotics FDA Approves New Powder Form of CF Drug TOBI®

The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).

| 1 min read
Antibiotics New Inhaled Antibiotic Cayston Gains Rapid and Broad Acceptance – 2010 NACFC

A key focus of this year's North American Cystic Fibrosis Conference (NACFC) was the progress of the more than 30 potential new therapies moving through the CF Foundation's drug development pipeline.

| 2 min read
Antibiotics New Inhaled Antibiotic Cayston Now Available for People with CF

A new inhaled antibiotic for the treatment of cystic fibrosis called Cayston® is now available for patients through select specialty pharmacies, including the CF Services Pharmacy. 

| 2 min read